Logo image of NTRB

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD

9.9  +2.56 (+34.88%)

After market: 10.19 +0.29 (+2.93%)

Fundamental Rating

2

Taking everything into account, NTRB scores 2 out of 10 in our fundamental rating. NTRB was compared to 195 industry peers in the Pharmaceuticals industry. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NTRB had negative earnings in the past year.
NTRB had a negative operating cash flow in the past year.
NTRB had negative earnings in each of the past 5 years.
In the past 5 years NTRB always reported negative operating cash flow.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

NTRB has a worse Return On Assets (-54.59%) than 63.98% of its industry peers.
NTRB has a Return On Equity of -60.96%. This is comparable to the rest of the industry: NTRB outperforms 52.69% of its industry peers.
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROIC N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

NTRB's Gross Margin of 31.59% is in line compared to the rest of the industry. NTRB outperforms 55.38% of its industry peers.
NTRB's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NTRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTRB has more shares outstanding
Compared to 5 years ago, NTRB has more shares outstanding
NTRB has a worse debt/assets ratio than last year.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

NTRB has an Altman-Z score of 32.68. This indicates that NTRB is financially healthy and has little risk of bankruptcy at the moment.
NTRB's Altman-Z score of 32.68 is amongst the best of the industry. NTRB outperforms 94.62% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that NTRB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, NTRB is in line with its industry, outperforming 58.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 32.68
ROIC/WACCN/A
WACC10.69%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

A Current Ratio of 4.96 indicates that NTRB has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.96, NTRB is doing good in the industry, outperforming 64.52% of the companies in the same industry.
A Quick Ratio of 4.83 indicates that NTRB has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.83, NTRB is doing good in the industry, outperforming 65.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.96
Quick Ratio 4.83
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

2

3. Growth

3.1 Past

NTRB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.01%.
NTRB shows a decrease in Revenue. In the last year, the revenue decreased by -3.18%.
NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 53.42% yearly.
EPS 1Y (TTM)-6.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.21%
Revenue 1Y (TTM)-3.18%
Revenue growth 3Y30.25%
Revenue growth 5Y53.42%
Sales Q2Q%50.19%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTRIBAND INC

NASDAQ:NTRB (1/23/2025, 9:21:48 PM)

After market: 10.19 +0.29 (+2.93%)

9.9

+2.56 (+34.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-10 2024-12-10
Earnings (Next)N/A N/A
Inst Owners2.38%
Inst Owner Change0%
Ins Owners54.05%
Ins Owner Change0%
Market Cap109.99M
Analysts82.86
Price TargetN/A
Short Float %2.2%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.4
P/FCF N/A
P/OCF N/A
P/B 9.79
P/tB 19.54
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.18
BVpS1.01
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.59%
FCFM N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.16%
Cap/Sales 6.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.96
Quick Ratio 4.83
Altman-Z 32.68
F-Score4
WACC10.69%
ROIC/WACCN/A
Cap/Depr(3y)22.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.21%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.18%
Revenue growth 3Y30.25%
Revenue growth 5Y53.42%
Sales Q2Q%50.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.09%
OCF growth 3YN/A
OCF growth 5YN/A